CSTL - NASDAQ
Castle Biosciences, Inc.
$19.71
+3.4%Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
At a Glance
Live SnapshotCastle Biosciences, Inc. Management Team
Mr. Tobin W. Juvenal
Chief Commercial Officer
Compensation
$883,192
Mr. Frank Stokes
Chief Financial Officer & Treasurer
Compensation
$926,744
Ms. Kristen M. Oelschlager R.N.
Chief Operating Officer
Compensation
$1,205,743
Mr. Derek J. Maetzold
Founder, Chief Executive Officer, President & Director
Compensation
$1,657,479
Dr. Matthew Goldberg M.D.
Senior Vice President of Medical
Ms. Keli Greenberg
Vice President of Human Resources
Ms. Camilla Zuckero
Vice President of Investor Relations & Corporate Affairs
Dr. Jay Braxton Pharm.D.
Vice President of Marketing & Brand Manager of Uveal Melanoma (UM)
Mr. Kevin Doman
Vice President of Sales
Castle Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have sold $7.84M worth of CSTL shares, with no buying activity reported.
3 Months
0
0.00
117.9K
3.01M
-3.0M
-$3.01M
3-6 Months
0
0.00
80.4K
2.94M
-2.9M
-$2.94M
6-9 Months
0
0.00
52.9K
1.89M
-1.9M
-$1.89M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Maetzold Derek J
Director, Officer: Pres. & Chief Exec. Officer
$4.54M
Oelschlager Kristen M
Officer: Chief Operating Officer
$1.25M
Juvenal Tobin W
Officer: Chief Commercial Officer
$1.24M
Stokes Frank
Officer: Chief Financial Officer
$670K
Cole G Bradley
Director
$135K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $7.84M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
CSTL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 08, 2026 | May 28, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 09, 2025 | May 22, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 10, 2024 | April 10, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 12, 2023 | April 12, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 21, 2022 | June 02, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 10, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 23, 2020 | June 04, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.